Skip to main content
. 2022 Nov 1;12(10):146. doi: 10.1038/s41408-022-00741-2

Fig. 5. Cumulative incidence of CRS and ICANS in multiple myeloma patients treated with anti-BCMA CAR T cells.

Fig. 5

Time to grade ≥2 CRS (A) and grade ≥1 ICANS (B) were estimated and compared by method of Gray, stratified by early G-CSF administration. The early G-CSF group (N = 24) received G-CSF within ≤2 days after CAR T, whereas the control group (N = 23) either received G-CSF ≥ 3 days after CAR T or were not exposed to G-CSF. 95% confidence intervals are represented by shading.